![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Resistance Analysis of Genotype 1 or 3 HCV-Infected Patients
Treated With
Sofosbuvir/Velpatasvir + GS-9857 for 6 or 8 Weeks
|
|
|
Reported by Jules Levin
EASL 2016 april 14-17 Barcelona
Edward J. Gane,1 Evguenia S. Svarovskaia,2 Hadas Dvory-Sobol,2 Robert H. Hyland,2 Luisa M. Stamm,2 Diana M. Brainard,2 Michael D. Miller,2 Hongmei Mo,2 Christian Schwabe,1 Catherine A. Stedman3
1Auckland Clinical Studies Ltd, Auckland, New Zealand; 2Gilead Sciences, Inc., Foster City, California, USA; 3Christchurch Clinical Studies Trust, Christchurch, New Zealand
![EASL1](../images/041516/041516-11/EASL1.gif)
![EASL2](../images/041516/041516-11/EASL2.gif)
![EASL3](../images/041516/041516-11/EASL3.gif)
![EASL4](../images/041516/041516-11/EASL4.gif)
![EASL5](../images/041516/041516-11/EASL5.gif)
![EASL6](../images/041516/041516-11/EASL6.gif)
![EASL7](../images/041516/041516-11/EASL7.gif)
![EASL8](../images/041516/041516-11/EASL8.gif)
![EASL9](../images/041516/041516-11/EASL9.gif)
![EASL10](../images/041516/041516-11/EASL10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|